Triple Negative Breast Cancer: Understanding Treatment Resistance and New Treatment Options

Format

Webcast

Time to Complete

1 hour

Released

November 5, 2012

Expires

October 18, 2014

Updated Expiration Information

This CME-certified activity has been granted an extension for twelve months as the content was deemed relevant and current according to the standards set forth by the Society for Translational Oncology (STO) and Massachusetts General Hospital.

Release date: November 5, 2012
Review: October 18, 2013
Expiration date: October 18, 2014

Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)^TM

Accredited Provider

Jointly sponsored by the Society for Translational Oncology and Massachusetts General Hospital.

Commercial Supporter

Supported through an educational grant from Genentech, Novartis, and Genomic Health

Program Description

Triple-negative breast cancer (TNBC) is highly resistant to treatment and remains the most challenging subtype of cancer to treat, particularly once it has progressed. It’s imperative for clinicians to stay informed regarding the growing understanding of crosstalk between growth factor signaling and ER pathways and the implications of this crosstalk for treating patients with endocrine-resistant tumors.

Intended Audience

Community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.

Educational Objectives

At the end of this online enduring material, participants should be able to:

Identify molecular pathways that contribute to endocrine and trastuzumab resistance and discuss their implications for treatment.
Discuss the outcomes of the most recent clinical trials related to the management of women with treatment-resistant breast cancer, including those with triple-negative breast cancer.

Faculty

It is the policy of The Society for Translational Oncology (STO) that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. The Society for Translational Oncology (STO) has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.

In accord with the disclosure policy of The Society for Translational Oncology (STO) as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.

Steven J. Isakoff, MD, PhD
Assistant in Medicine
MGH Cancer Center
Massachusetts General Hospital
Instructor in Medicine
Harvard Medical School
Boston, MA

The following speaker of this activity has indicated that he and/or his spouse/partner do have a relevant financial relationship to disclose:

Steven J. Isakoff, MD, PhD
Consulting/Advisory Board: Myriad Genetics
Research Funding: Abbott Pharmaceuticals

Planner Disclosure

The following planner of this activity has indicated that she or her spouse/partner do have a relevant financial relationship to disclose:

Beverly Moy, MD
Consulting: GlaxoSmithKline, Pfizer

Media

The Internet was selected as the medium for this activity to accommodate the learning preferences of a significant portion of the target audience.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)^TM

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Society for Translational Oncology (STO) and Massachusetts General Hospital. The Society for Translational Oncology (STO) is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Designation Statement

Society for Translational Oncology designates this enduring material for a maximum of one (1) AMA PRA Category 1 Credit^TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Instructions

Method of Participation:
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

myCME Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements

A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

Add to Queue